Androgen suppression strategies for prostate cancer: is there an ideal approach?
Publication/Presentation Date
6-1-2011
Abstract
Androgen suppression therapy (AST) was first described in 1941 as a treatment of prostate cancer (PCa) and remains the mainstay of therapy in patients with hormone-naïve metastatic disease. It also is used in locally advanced or recurrent disease and in combination with radiation therapy in patients with higher-risk features. Several approaches to AST have been developed as a result of increased understanding of the pathways controlling testosterone production. Increased recognition of the side effects has resulted in strategies to minimize complications associated with AST. Attempts to reduce AST adverse effects include intermittent hormonal therapy and methods to reduce amount of intracellular androgens without reducing the circulating testosterone levels.
Volume
12
Issue
3
First Page
188
Last Page
196
ISSN
1534-6285
Published In/Presented At
Ismail, M., Ferroni, M., & Gomella, L. G. (2011). Androgen suppression strategies for prostate cancer: is there an ideal approach?. Current urology reports, 12(3), 188–196. https://doi.org/10.1007/s11934-011-0178-0
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
21384154
Department(s)
Administration and Leadership
Document Type
Article